ArticleJIMD reports2025
A Single-Center Retrospective Cohort Study of Biopterin Metabolism Disorders in the United Arab Emirates.
Article in JIMD reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Follow-up and outcome of patients with primary BH4 deficiencies.Frontiers in neurologyPooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tetrahydrobiopterin (BH4) deficiencies comprise a group of five neurometabolic disorders caused by five genetic defects responsible for BH4 biosynthesis and regeneration. Their global prevalence remains unknown, and variance exists among different countries. Aims: To describe clinical, biochemical, molecular genetic data and follow-up of patients with BH4 deficiency seen in Tawam Hospital. Methods: A retrospective study of all patients with BH4 disorders who were followed up between January 2010 and December 2023 in Tawam Hospital. All data were retrieved from patients' electronic charts, including baseline characteristics, developmental milestones, family history, and clinical examination. Radiological and laboratory investigations, including phenylalanine levels, prolactin levels, CSF study, urine and plasma pterin profiles, and molecular tests, were reviewed. Results: Ten patients with BH4 deficiencies were found. The youngest patient was diagnosed at 3- weeks, and the oldest was nine; 70% were male, consanguineous 80%, and 40% were Emirati. Prematurity was reported in two patients. Intrauterine growth restriction was found in 70%, and microcephaly in 40%. Eighty percent had developmental delay, and 2 patients had behavioral issues. Seizure and movement disorders were reported in five and three patients, respectively. Brain MRI showed cortical atrophic changes, corpus callosum hypoplasia, hyperintensities in the parieto-occipital region, and periventricular white matter. Abnormal Newborn screening was found in 60%, with initial high phenylalanine levels (>120 μmol/L) in 80%. Prolactin level was high in all studied patients. Four patients' cerebrospinal fluid neurotransmitter metabolites were evaluated. Blood for DHPR screening and urine pterin profile were done on eight patients. Nine patients had molecular testing. DHPR deficiency was most commonly reported among studied patients (50%), with five novel variants in the Conclusion: This cohort offers an in-depth clinical and genetic understanding of BH4 deficiencies from a single center in the UAE. It describes new genetic variants and addresses diagnostic challenges to enhance the patient's diagnosis and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.